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Abstract
Background: The prevalence of non-alcoholic fatty liver dis-
ease (NAFLD) affecting children and adolescents has in-
creased dramatically in recent years. This increase is most 
probably related to the obesity pandemic and the high con-
sumption of fructose. However, hepatic steatosis has some 
rare causes (e.g., some metabolic diseases) of which clini-
cians should be aware, particularly (but not only) when pa-
tients are non-obese or non-overweight. Differential diagno-
sis is notably important when pathologies have a specific 
treatment, such as for glycogenosis type IX (GSD-IX). Aims: 
To contribute to the knowledge on the differential diagnosis 
of NAFLD in paediatric age and to the clinical, biochemical, 
molecular, and histological characterisations of GSD-IX, a 
rare metabolic disorder. Methods: We performed a retro-
spective study of a small series of cases (n = 3) of GSD-IX di-
agnosed in the past 6 years, who were currently being fol-
lowed up in the Units of Gastroenterology or Metabolic Dis-
eases of the Paediatric Division of our hospital and whose 
clinical presentation was NAFLD in paediatric age. Results: 
Three male patients were diagnosed with NAFLD before 2 
years of age, 2 with confirmed diagnosis before the age of 3 
years (alanine aminotransferase [ALT], liver ultrasound, and 
molecular analysis) and 1 whose diagnosis was confirmed at 
11 years (ALT, liver ultrasound, liver histology, and molecular 
analysis). None of the patients were obese or overweight, 
and the daily fructose consumption was unknown. The out-
come was favourable in all 3 patients, with follow-up periods 
ranging from 2 to 6 years. Conclusion: The decision on how 
far the search for secondary causes of NAFLD should go can 
be difficult, and GSD-IX must be on the list of possible causes.
© 2019 Sociedade Portuguesa de Gastrenterologia 
Published by S. Karger AG, Basel
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Resumo
Introdução: A prevalência de fígado gordo não-alcoólico 
(NAFLD) afetando crianças e adolescentes, aumentou 
enormemente nos últimos anos. Este aumento está muito 
provavelmente relacionado com a pandemia de obesi-
dade e o elevado consumo de fructose. No entanto, a es-
teatose hepática pode ser causada por algumas entidades 
raras (por exemplo, doenças metabólicas) para as quais os 
clínicos devem estar alertados, particularmente (mas não 
só) quando os doentes não são obesos nem têm excesso 
de peso. O diagnóstico diferencial é especialmente im-
portante quando as patologias têm um tratamento espe-
cífico, como é o caso da Glicogenose tipo IX (GSD-IX). Ob-
jetivos: Contribuir para o conhecimento dos diagnósticos 
diferenciais de NAFLD em idade pediátrica, e contribuir 
para a caracterização clínica, bioquímica, molecular e his-
tológica da GSD-IX, uma doença metabólica rara. Metodo-
logia: Estudo retrospectivo de uma pequena série de ca-
sos (n = 3) de GSD-IX diagnosticados nos últimos 6 anos, 
atualmente em seguimento nas Unidades de Gastren-
terologia ou de Doenças Metabólicas do Serviço de Pe-
diatria do nosso hospital, e cuja forma de apresentação 
clínica foi NALFLD em idade pediátrica. Resultados: Três 
doentes de sexo masculino foram diagnosticados com 
NAFLD antes dos 2 anos de idade, dois com diagnóstico 
confirmado antes dos 3 anos (alanina aminotransferase 
[ALT], ecografia hepática, e estudo molecular), e um cujo 
diagnóstico foi confirmado aos 11 anos (ALT, ecografia e 
histologia hepáticas, e estudo molecular). Nenhum dos 
doentes era obeso ou tinha excesso de peso, e o consumo 
diário de frutose era desconhecido. A evolução foi fa-
vorável nos três doentes, com um tempo de seguimento 
que variou entre 2 e 6 anos. Conclusões: A decisão sobre 
até onde a pesquisa de causas secundárias de NAFLD 
deve ir pode ser difícil, e a GSD-IX deve estar na lista de 
causas possíveis. © 2018 Sociedade Portuguesa de Gastrenterologia 
Published by S. Karger AG, Basel
Introduction
Non-alcoholic fatty liver disease (NAFLD) is currently 
the most common cause of fatty liver both in children and 
adults [1, 2] and is already the most common cause of 
chronic liver disease in children and adolescents [3]. Un-
favourable lifestyles leading to obesity and a high-fruc-
tose diet may be the causes [4]. NAFLD is characterised 
by fatty infiltration of the liver (more than 5% of hepato-
cytes) in the absence of secondary causes, such as alcohol 
or drug consumption, infections, malnutrition, and ge-
netic/metabolic diseases. Therefore, the diagnosis of 
NAFLD is one of exclusion, and it is particularly impor-
tant to exclude diseases with specific treatment [5]. 
Among the metabolic diseases to be considered are some 
glycogen storage diseases (GSDs) [6].
The GSDs are a group of inherited metabolic disorders 
that result from a defect in any of the various enzymes 
required for the synthesis or degradation of glycogen 
(Fig.  1). They are divided into two groups: GSDs with 
liver involvement (GSD-0, I, III, IV, VI, IX) or those as-
sociated with neuromuscular disease or both. The glyco-
gen storage disease type IX (GSD-IX) is one of the most 
common forms of GSD (25% of cases; estimated frequen-
cy of 1/100,000) and result from a defect in an enzyme 
required for the degradation of glycogen. The enzymatic 
blockage leads to elevated pyruvate levels, which will be 
converted to lactate and acetylcoenzyme A. The latter is 
the starting point of the liver lipogenesis pathway with 
fatty acids and triglyceride synthesis. Although the main 
substrate accumulated in the target organs is glycogen, 
there may be a predominance of lipids, particularly in the 
liver [7, 8].
GSD-IX is both genetically and clinically heteroge-
neous. It is caused by deficiency in hepatic phosphorylase 
kinase (PhK), which is composed of four subunits (α, β, 
γ, and δ) with each one encoded by a different gene. GSD-
IX subtypes are identified according to the affected sub-
unit (GSD-IXa, GSD-IXb, GSD-IXc, and GSD-IXd) and 
exhibit different modes of transmission: X-linked reces-
sive for the PHKA2 gene (subtype α, 75% of all GSD-IX) 
and autosomal recessive for the PHKB (subtype β) and 
PHKG2 (subtype γ) genes. The correlation genotype-
phenotype is not clear but patients with PHKG2 muta-
tions (GSD-IXc) have been reported to have the most se-
vere phenotypes, and the most common subtype (GSD-
IXa) has been characterised with a wide variability. Even 
if the majority of the patients have a benign course in the 
long term, with mild symptoms in childhood improving 
with age, some may progress to liver cirrhosis [9, 10] or 
develop liver adenomas and hepatocarcinoma in adult-
hood [11].
Case Report
We describe a small series of cases (n = 3) of GSD-IX, subtype 
α (GSD-IXa), diagnosed and managed in our outpatient clinic in 
the past 6 years and whose clinical presentation was fatty liver dur-
ing paediatric age. Data were collected from clinical records. We 
analysed the clinical, analytical, histological, and molecular genet-
ics parameters. 
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Fig. 1. Simplified scheme for the synthesis and degradation of glycogen and its enzymatic defects in several types 
of glycogenesis.
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Results
Case 1
A male infant, the first and only child of a healthy non-
related couple, was born after a 40-week pregnancy, with 
a weight of 3,080 g (p10–50) and a length of 48.5 cm (p10). 
At 18 months of age, he was hospitalised for bacterial 
pneumonia, and had hepatosplenomegaly and elevated 
transaminases (aspartate aminotransferase [AST]: 67 
IU/L; alanine aminotransferase [ALT]: 53 IU/L). AST 
Table 1. Baseline clinical and analytical features of patients at admission to the referral centre
Case 1 Case 2 Case 3 Reference 
values
Clinical features 
Sex M M M
Age (year of birth) 11 years (2000) 15 months (2010) 18 months (2013)
Parental consanguinity no no no
Family history negative negative negative
Weight, kg/percentile 43.6/p50–85 11.0/p50–85 11.0/p50
Length or height, cm/percentile 150.5/85 80/p50–85 82/p50
BMI, kg/m2/percentile 19.25/p50–85 17.2/p50–85 16.4/p50–85
Hepatomegaly no yes (5 cm) yes (3.5 cm)
Splenomegaly no no no
Biochemical parameters
Total bilirubin, mg/dL 0.28 0.16 0.26 0.20–1.00
Conjugated bilirubin, mg/dL 0.10 0.06 0.10 0.00–0.20
AST, IU/L 26 150 158 10–34
ALT, IU/L 16 219 60 10–44
γGT, IU/L 13 35 24 10–66
CPK, IU/L 136 95 NA 24–204
Glucose, mg/dL 77 66 74 70–105
Bicarbonates, mmol/L 17.5 17.9 15.4 22.0–29.0
Lactate, mmol/L 1.2 1.28 1.63 0.5–2.20
Uric acid, mg/dL 4.7 3.4 4.0 2.0–5.5
Total cholesterol, mg/dL 174 174 196 0–200
LDL cholesterol, mg/dL 94 116 136 0–130
HDL cholesterol, mg/dL 70 13 25 35–55
VLDL cholesterol, mg/dL 10 45 35 3–56
Triglycerides, mg/dL 50 227 174 40–160
Other exams performed after 
Hepatitis A, B, and C
CMV
EBV
negative
IgG + IgM –
IgG + IgM –
negative
IgG – IgM –
IgG – IgM –
negative
IgG+ IgM –
IgG + IgM – 
Serum alpha-1-antitrypsin, mg/dL normal normal normal
Serum ferritin, ng/mL 22 NA NA 12.8–454
Transferrin saturation rate, % 10 NA NA 15–45
Serum caeruloplasmin, mg/dL 26 NA NA 16–36
24-h urinary copper, μmol/d 1.086 ND ND 0.040–0.050
Copper in liver tissue, µg/g 24.82 ND ND <40
Sweat test ND normal ND
LAL activity (in leucocytes) normal ND normal
Molecular studies
PhKA2 gene mutation c.1054C>T 
(p.352X) exon 11 in 
hemizygosity
mutation c.892C>T (p.
R298X) exon 9 in 
hemizygosity
mutation c.706G>T 
(p.E236*) exon 7 in 
hemizygosity
BMI, body mass index; CMV, cytomegalovirus; EBV, Epstein-Barr virus; LAL, lysosomal acid lipase; NA, non-available; ND, not 
done.
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and ALT eventually normalised, but hepatosplenomegaly 
persisted and led to admission to our outpatient clinic 
when he was 25 months old. Upon admission, comple-
mentary investigation was normal and included creatine 
phosphokinase, alpha-1-antitrypsin, hepatitis C virus an-
tibodies, ceruloplasmin, serum ferritin, transferrin satu-
ration, and serum lipids. Throughout the following years, 
spleen dimensions returned to normal, but the liver re-
mained slightly enlarged with hyper-echogenicity. When 
the patient was 5 years old, the enzymatic activity in the 
leucocytes for glycogen storage disease type III (GSD-III) 
was normal. He was discharged by his attending physi-
cian, and performing annual abdominal ultrasound ex-
aminations was recommended.
By the age of 11 years, the abdominal ultrasound main-
tained a diffuse liver hyper-echogenicity, a pattern sug-
gesting steatosis. The laboratory tests performed are pre-
sented in Table 1. Liver histology revealed macro- and 
micro-steatosis without inflammatory infiltrates or fibro-
sis (Fig. 2). The copper level in the liver tissue was normal. 
The molecular study confirmed the previously described 
mutation c.1054C>T (p. 352X) exon 11 in hemizygosity 
on the PHKA2 gene. Dietary measures were prescribed. 
Currently, at 18 years of age, the patient is asymptomatic; 
transaminases and other liver function tests remain nor-
mal; the liver maintains a pattern of steatosis in ultra-
sound with no adenomas; and the spleen is in the upper 
limit of normal size. His mother has normal ALT and has 
not undergone liver ultrasound or molecular study.
Case 2
A male infant, the second child of a healthy non-relat-
ed couple, was born after a 37-week pregnancy with a 
weight of 2,750 g (p10–50) and a length of 46.5 cm (p10–
50). He developed physiological jaundice that resolved 
within a week without phototherapy. During his first 
months, he had several episodes of wheezing, which were 
treated with montelukast and fluticasone in aerosol. At 11 
months of age, during a wheezing episode, his transami-
nases (AST 158 IU/L; ALT 155 IU/L) and triglycerides 
(180 mg/dL) were elevated. At 15 months, he was admit-
ted to our hospital for hepatomegaly (6 cm below the cos-
tal grid, smooth surface, and thin edge) and persistently 
elevated transaminases; abdominal ultrasound showed 
an enlarged and hyperechogenic liver with a steatosis pat-
tern; the spleen was normal in size. The laboratory tests 
highlighted the slightly low fasting glycemia and bicar-
bonate, discreetly increased triglycerides and normal se-
rum uric acid (Table 1). Cardiac evaluation was normal. 
Molecular study showed a previously described causal 
mutation on the PHKA2 gene [c.892C>T (p. R298X – 
exon 9)] with a hemizygosity pattern, confirming GSD-
IXa. Dietary measures were prescribed. Two years later, 
hepatomegaly remained the same, although the transam-
inases normalised. Bicarbonates were slightly low and 
uric acid elevated. Currently, at 8 years old, he has no 
signs of progression to chronic liver disease or adenomas. 
His older sister (16 years old) is asymptomatic, with nor-
mal ALT and liver ultrasound. His mother has normal 
200 μm 100 μma b
Fig. 2. a, b Liver histology in case 1 (at 11 years of age) showing macro- and micro-steatosis; hepatocytes with 
preserved morphology, and dimensions within normal ranges, without inflammatory infiltrate or fibrosis (H&E 
100×).
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ALT and has not undergone liver ultrasound or molecu-
lar study.
Case 3
A male infant, the first and only child of a healthy non-
related couple, was born after a 39-week high-risk preg-
nancy due to placental displacement, with a weight of 
3,300 g (p10–50) and a length of 51 cm (p50). In the first 
week, he developed jaundice (total bilirubin 17.3 mg/dl) 
that was treated with phototherapy. During the first 8 
months, he had multiple infections: urinary tract infec-
tion caused by Escherichia coli, acute gastroenteritis, fever 
of undetermined origin, septicaemia caused by Neisseria 
meningitidis, upper respiratory infection caused by Coro-
navirus, cystitis caused by Proteus mirabilis, acute bron-
chiolitis followed by acute otitis media and an episode of 
bacteraemia of unknown origin. This overwhelming 
number of infections led to an investigation on humoral 
and the cellular immunity defects. A study performed out 
of context of infection excluded a complement deficiency 
and revealed normal serum immunoglobulins and im-
munophenotyping of lymphocytes. Throughout all these 
infectious episodes, the patient had palpable hepatomeg-
aly and consistently elevated transaminases. At 18 months, 
abdominal ultrasound showed an enlarged liver with a 
pattern suggestive of steatosis and a normal-sized spleen. 
Table 1 presents the laboratory tests performed. One year 
later, molecular study confirmed the new and unrecog-
nized mutation c.706G>T (p. E236*) exon 7 in hemizy-
gosity in the PhKA2 gene, which leads to the production 
of a truncated protein. Diet measures were prescribed. 
Recurrent infections ceased after the first year of life. Cur-
rently, at 5 years of age, the patient is doing well, with 
slight hepatomegaly (2 cm below the costal margin) and 
normal ALT (Fig. 3) and other liver function tests, and 
maintains a liver steatosis pattern on ultrasound. His 
mother is a carrier of heterozygosity, with normal ALT 
and liver pattern on ultrasound.
Discussion/Conclusion
NAFLD is one of the comorbidities of obesity, and its 
incidence is increasing dramatically. In addition, NAFLD 
has been associated with a certain dietary pattern, even 
without obesity or overweightness. Nonetheless, fatty liv-
er can also be secondary to a large number of other enti-
ties [5]. Therefore, a child with fatty liver, regardless of 
the child’s body mass index, is a challenging issue. The 
challenges are in the following order: when to suspect 
NAFLD, how to confirm the diagnosis, how to accom-
plish its staging, and how to rule out secondary causes.
None of our 3 patients was obese or overweight. How-
ever, we were not able to establish with reasonable accu-
racy their daily consumption of fructose. All 3 had hepa-
tomegaly and elevated transaminases. For this reason, 
they underwent an abdominal ultrasound that confirmed 
an enlarged liver with hyper-echogenic pattern. These 
findings were suggestive of fatty liver.
ALT is currently the best screening method for fatty 
liver in children aged ≥10 years, with 88% sensitivity and 
26% specificity for values > 2 times the normal value [12]. 
Liver ultrasound may show a suggestive pattern, although 
sensitivity is low. Liver histology is the gold standard for 
diagnosis, but it is too invasive as a screening method and 
has some limitations [13]. Magnetic resonance imaging 
(MRI) and spectroscopy (MRS) were validated and have 
showed to be accurate to detect and quantify hepatic ste-
atosis in both adults [14] and children [15]. In fact, MRI-
estimated proton density fat fraction is currently the most 
accurate test to quantify liver steatosis and can already be 
considered the gold standard [16]. However, it is usually 
unavailable and cannot be considered a ‘non-invasive’ 
procedure in young children because it requires sedation. 
For staging NAFLD, liver histology is still the best meth-
od for distinguishing NAFL from non-alcoholic steato-
hepatitis and for revealing the presence or absence of ad-
vanced fibrosis/cirrhosis, whereas some non-invasive 
methods are still in development [16].
Only 1 of our 3 patients (case 1) had fatty liver con-
firmed through histology at 11 years old, when his age 
and the increased level of 24-h urinary copper prompted 
us to investigate for Wilson’s disease [17]. In the other 2 
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Fig. 3. Transaminases during follow-up in case 2.
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(cases 2 and 3), the diagnosis was presumptive and based 
on increased ALT and suggestive liver pattern in the ul-
trasound. The execution of MRI or MRS and liver biopsy 
was not considered because the benign clinical status of 
the patients did not justify the performance of invasive 
examinations. Moreover, the confirmation of a secondary 
cause that can be associated with lipids accumulation in 
the liver, such as GSD-IXa [7, 8], reinforces this presump-
tion.
The guidelines are scarce concerning the ruling out of 
secondary causes of fatty liver. The North American So-
ciety of Pediatric Gastroenterology, Hepatology and Nu-
trition (NASPGHAN) guidelines for diagnosis and treat-
ment of NAFLD (2017) do not provide enough orienta-
tion to a cost-benefit approach regarding who should be 
screened and when for each listed genetic/metabolic dis-
ease [13]. Furthermore, the GSD-IX is not even men-
tioned on their list as a secondary cause of fatty liver.
In this case series, we prioritised the exclusion of dis-
eases with specific treatment and considered the patient’s 
age. When the patient reached the age of 11 years, we 
searched for Wilson’s disease, juvenile haemochromato-
sis, lysosomal acid lipase deficiency [18], and GSD types 
VI and IX. In patient 2, the hypothesis of drug hepatotox-
icity by montelukast was considered, and it could had ex-
plained the increased transaminases but not the hepato-
megaly and steatosis. In patient 3, we considered the hy-
pothesis of congenital immunodeficiency with liver 
injury but were not able to confirm it. For the last 2 pa-
tients, lysosomal acid lipase deficiency was also consid-
ered but was tested only in patient 3. The diagnosis of 
GSD-IXa was confirmed by molecular study in all pa-
tients. All patients had pathogenic mutations of X-linked 
transmission in the PHKA2 gene. In case 2, a new muta-
tion was found, which results in a premature stop codon. 
This new mutation was accepted as a causal mutation.
The clinical presentation of GSD-IXa is generally 
milder than that of other GSDs (and similar to GSD-VI), 
and its symptoms (hepatomegaly, growth retardation, el-
evated transaminases, hypertriglyceridaemia, and some-
times ketosis and hypotonia) typically improve with age, 
as it is usually asymptomatic in adulthood [19]. However, 
the genetic variants in PHKA2 have a broad phenotypic 
spectrum, including progression to cirrhosis [9, 10] and 
the development of hepatic adenomas [11] as well as less 
common phenotypes with kidney dysfunctions due to re-
nal tubular acidosis and central nervous system involve-
ment with delayed cognitive and speech abilities [20]. 
Thus far, our patients’ clinical course has been benign, 
including the oldest. 
The treatment includes dietary measures, namely, a 
high-protein diet (2–3 g/kg) with restriction of simple 
(added) sugars, avoidance of prolonged fasting, and sup-
plementation of raw corn starch in the most severe phe-
notypes to maintain glucose concentrations and prevent 
ketosis overnight. In situations of greater stress, water 
infusion with maltodextrin (5 g/100 mL) is recommend-
ed. Rarely, hyperuricaemia or metabolic acidosis must be 
addressed. Untreated children may have undesirable re-
percussions, such as morning sickness, which affects 
school performance, and growth retardation, which 
causes psychological distress [21]. All our patients had 
low serum bicarbonates at presentation (later nor-
malised), but none had hyperlactacidaemia or growth 
failure. Moreover, hyperuricaemia was not a problem in 
any of them.
Although the majority of patients are male, females 
may also exhibit symptoms, either in autosomal recessive 
forms or in the X-linked transmission subtype (GSD-
IXa), because of the lyonisation phenomenon [22, 23]. 
Therefore, the mother, sisters, and daughters of male pa-
tients should be screened. In addition to the usual (mild-
er) symptoms, women may have polycystic ovary syn-
drome. The transition to adulthood should include an 
adequate surveillance plan for cirrhosis, adenomas, and 
hepatocarcinoma.
In summary, making the decision of when and how to 
search for secondary causes of NAFLD can be challeng-
ing. To serve this purpose, more appropriate and cost-
effective guidelines are needed. GSD-IX should be in-
cluded in these guidelines because liver involvement can 
range in a spectrum from steatosis to steatohepatitis, with 
or without variable degrees of fibrosis/progression to liv-
er cirrhosis. As several genetic/metabolic diseases can be 
among the secondary causes of NAFLD, the development 
of a next-generation sequencing panel, including all those 
diseases, can be a useful tool in the management of these 
patients [24].
Statement of Ethics
The authors have no ethical conflicts to disclose.
Disclosure Statement
The authors have no conflicts of interest to declare.
Fatty Liver Caused by Glycogenosis Type 
IX
437GE Port J Gastroenterol 2019;26:430–437
DOI: 10.1159/000496571
Author Contributions
Dr. Catarina Leuzinger Dias collected and analysed data and 
elaborated the manuscript, which is based on her Master thesis 
of medicine. Dr. Inês Maio, Dr. José Ricardo Brandão, Dr. Edite 
Tomás, and Prof. Doutora Esmeralda Martins collected and an-
alysed data and then evaluated and approved the manuscript. 
Dr. Ermelinda Santos Silva elaborated the study design, collect-
ed and analysed data, and evaluated and approved the manu-
script.
References
 1 Nobili V, Socha P. Pediatric nonalcoholic fat-
ty liver disease: current thinking. J Pediatr 
Gastroenterol Nutr. 2018 Feb; 66(2): 188–92.
 2 Mann JP, Valenti L, Scorletti E, Byrne CD, 
Nobili V. Nonalcoholic fatty liver disease in 
children. Semin Liver Dis. 2018 Feb; 38(1): 1–
13.
 3 Anderson EL, Howe LD, Jones HE, Higgins 
JP, Lawlor DA, Fraser A. The Prevalence of 
non-alcoholic fatty liver disease in children 
and adolescents: a systematic review and me-
ta-analysis. PLoS One. 2015 Oct; 
10(10):e0140908.
 4 Mosca A, Nobili V, De Vito R, Crudele A, 
Scorletti E, Villani A, et al. Serum uric acid 
concentrations and fructose consumption are 
independently associated with NASH in chil-
dren and adolescents. J Hepatol. 2017 May; 
66(5): 1031–6.
 5 Kneeman JM, Misdraji J, Corey KE. Second-
ary causes of nonalcoholic fatty liver disease. 
Therap Adv Gastroenterol. 2012 May; 5(3): 
199–207.
 6 Chen MA, Weinstein DA. Glycogen storage 
diseases: diagnosis, treatment and outcome. 
Transl Sci Rare Dis. 2016; 1(1): 45–72.
 7 Bali DS, Goldstein JL, Fredrickson K, Rehder 
C, Boney A, Austin S, et al. Variability of dis-
ease spectrum in children with liver phos-
phorylase kinase deficiency caused by muta-
tions in the PHKG2 gene. Mol Genet Metab. 
2014 Mar; 111(3): 309–13.
 8 Bali DS, Goldstein JL, Fredrickson K, Austin 
S, Pendyal S, Rehder C, et al. Clinical and mo-
lecular variability in patients with PHKA2 
variants and liver phosphorylase b kinase de-
ficiency. JIMD Rep. 2017; 37: 63–72.
 9 Johnson AO, Goldstein JL, Bali D. Glycogen 
storage disease type IX: novel PHKA2 mis-
sense mutation and cirrhosis. J Pediatr Gas-
troenterol Nutr. 2012 Jul; 55(1): 90–2.
10 Tsilianidis LA, Fiske LM, Siegel S, Lumpkin 
C, Hoyt K, Wasserstein M, et al. Aggressive 
therapy improves cirrhosis in glycogen stor-
age disease type IX. Mol Genet Metab. 2013 
Jun; 109(2): 179–82.
11 Roscher A, Patel J, Hewson S, Nagy L, Feigen-
baum A, Kronick J, et al. The natural history 
of glycogen storage disease types VI and IX: 
long-term outcome from the largest metabol-
ic center in Canada. Mol Genet Metab. 2014 
Nov; 113(3): 171–6.
12 Schwimmer JB, Newton KP, Awai HI, Choi 
LJ, Garcia MA, Ellis LL, et al. Paediatric gas-
troenterology evaluation of overweight and 
obese children referred from primary care for 
suspected non-alcoholic fatty liver disease. 
Aliment Pharmacol Ther. 2013 Nov; 38(10): 
1267–77.
13 Vos MB, Abrams SH, Barlow SE, Caprio S, 
Daniels SR, Kohli R, et al. NASPGHAN clini-
cal practice guideline for the diagnosis and 
treatment of nonalcoholic fatty liver disease 
in children: recommendations from the ex-
pert committee on NAFLD (ECON) and 
the North American Society of Pediatric Gas-
troenterology, Hepatology and Nutrition 
(NASPGHAN). J Pediatr Gastroenterol Nutr. 
2017 Feb; 64(2): 319–34.
14 Murphy P, Hooker J, Ang B, Wolfson T, 
Gamst A, Bydder M, et al. Associations be-
tween histologic features of nonalcoholic fatty 
liver disease (NAFLD) and quantitative diffu-
sion-weighted MRI measurements in adults. J 
Magn Reson Imaging. 2015 Jun; 41(6): 1629–
38.
15 Schwimmer JB, Middleton MS, Behling C, 
Newton KP, Awai HI, Paiz MN, et al. Mag-
netic resonance imaging and liver histology as 
biomarkers of hepatic steatosis in children 
with nonalcoholic fatty liver disease. Hepatol-
ogy. 2015 Jun; 61(6): 1887–95.
16 Wong VW, Adams LA, de Lédinghen V, 
Wong GL, Sookoian S. Noninvasive biomark-
ers in NAFLD and NASH - current progress 
and future promise. Nat Rev Gastroenterol 
Hepatol. 2018 Aug; 15(8): 461–78.
17 Socha P, Janczyk W, Dhawan A, Baumann U, 
D’Antiga L, Tanner S, et al. Wilson’s Disease 
in Children: A Position Paper by the Hepatol-
ogy Committee of the European Society for 
Paediatric Gastroenterology, Hepatology and 
Nutrition. J Pediatr Gastroenterol Nutr. 2018 
Feb; 66(2): 334–44.
18 Himes RW, Barlow SE, Bove K, Quintanilla 
NM, Sheridan R, Kohli R. Lysosomal acid li-
pase deficiency unmasked in two children 
with nonalcoholic fatty liver disease. Pediat-
rics. 2016 Oct; 138(4):e20160214.
19 Burda P, Hochuli M. Hepatic glycogen stor-
age disorders: what have we learned in recent 
years? Curr Opin Clin Nutr Metab Care. 2015 
Jul; 18(4): 415–21.
20 Burwinkel B, Amat L, Gray RG, Matsuo N, 
Muroya K, Narisawa K, et al. Variability of 
biochemical and clinical phenotype in X-
linked liver glycogenosis with mutations in 
the phosphorylase kinase PHKA2 gene. Hum 
Genet. 1998 Apr; 102(4): 423–9.
21 Schippers HM, Smit GP, Rake JP, Visser G. 
Characteristic growth pattern in male X-
linked phosphorylase-b kinase deficiency 
(GSD IX). J Inherit Metab Dis. 2003; 26(1): 
43–7.
22 Cho SY, Lam CW, Tong SF, Siu WK. X-linked 
glycogen storage disease IXa manifested in a 
female carrier due to skewed X chromosome 
inactivation. Clin Chim Acta. 2013 Nov; 426: 
75–8.
23 Blanco Sánchez T, Canedo Villarroya E, Mar-
tínez Zazo A, Pérez González B, Pedrón Giner 
C. Afectación hepática de paciente portadora 
en heterocigosis de una mutación en el gen 
PHKA2. An Pediatr (Barc). 2016; 85: 267–8. 
Spanish.
24 Nicastro E, D’Antiga L. Next generation se-
quencing in pediatric hepatology and liver 
transplantation. Liver Transpl. 2018 Feb; 
24(2): 282–93.
